| Issue Date | Title | Author(s) |
| 7-Jul-2021 | Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes | Yu, Sijian; Fan, Zhiping; Ma, Liping; Wang, Yu; Huang, Fen; Zhang, Qing; Huang, Jiafu; Wang, Shunqing; Xu, Na; Xuan, Li; Xiong, Mujun; Han, Lijie; Sun, Zhiqiang; Zhang, Hongyu; Liu, Hui; Yu, Guopan; Shi, Pengcheng; Xu, Jun; Wu, Meiqing; Guo, Ziwen; Xiong, Yiying; Duan, Chongyang; Sun, Jing; Liu, Qifa; Zhang, Yu |
| 15-Nov-2022 | Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia | Weng, Guangyang; Zhang, Yu; Yu, Guopan; Xu, Na; Sun, Zhiqiang; Lin, Dongjun; Liang, Xinquan; Deng, Lan; Xiao, Jie; Zhang, Hongyu; Guo, Ziwen; Jin, Hua; Du, Xin; Liu, Qifa |
| Dec-2023 | Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2 | Wang, Jun; Shao, Liang; Liang, Jing; Wu, Qingming; Zhu, Baoli; Deng, Qiwen; Liu, Zelin; Liu, Liqiong; Wang, Danyu; Yu, Zhijian; Tan, Xiaohua; Wang, Fuxiang; Meng, Jingye; Xu, Xiaojun; Xia, Zhongjun; Li, Zhiming; Wang, Hua; Wang, Liang; Wu, Wei; Xie, Qi; Huang, Xiaoxing; Sun, Zhiqiang; Zhang, Yu; Zhou, Hao; Zhou, Hui; Yang, Wenyan; Ren, Hua; Liu, Zhe; Qiao, Mingqiang; Tang, Feifei; Qi, Xiaofei; Wu, Huijing; Deng, Lijuan; Gao, Li; Zhang, Hongyan; Chen, Peng; Zhang, Hongyu; Zhang, Xinyou; Zhou, Jihao; Tu, Chuanqing; Guan, Ling; Yin, Qian; Shu, Rong; Chen, Feng; He, Mingxin; Wang, Qiang; Guo, Zhi |
| Aug-2024 | Chinese guidelines for integrated diagnosis and treatment of intestinal microecology technologies in tumor application (2024 Edition) | Wang, Qiang; He, Mingxin; Liang, Jing; Tan, Xiaohua; Wu, Qingming; Wang, Jun; Li, Xiaoan; Qiao, Mingqiang; Huang, Ziming; Xie, Qi; Liu, Zhe; Ren, Hua; Wang, Liang; Zhou, Hao; Shao, Liang; Shu, Rong; Wu, Wei; Yang, Wenyan; Wang, Hua; Sun, Zhiqiang; Xu, Xiaojun; Zhang, Xingding; Li, Zhiming; Zhang, Yu; Meng, Jingye; Zhu, Yanli; Chen, Feng; Qu, Rong; Chen, Peng; Li, Shuluan; Shi, Yuanyuan; Mao, Xin; Hu, Bichuan; Zhang, Yukui; Cao, Yu J.; Guo, Zhi |
| 6-Dec-2021 | Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes | Yu, Sijian; Lin, Tong; Nie, Danian; Zhang, Yu; Sun, Zhiqiang; Zhang, Qing; Wang, Caixia; Xiong, Mujun; Fan, Zhiping; Huang, Fen; Xu, Na; Liu, Hui; Yu, Guopan; Zhang, Hongyu; Shi, Pengcheng; Xu, Jun; Xuan, Li; Guo, Ziwen; Wu, Meiqing; Han, Lijie; Xiong, Yiying; Sun, Jing; Wang, Yu; Liu, Qifa |
| Nov-2022 | Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia | Weng, Guangyang; Zhang, Yu; Yu, Guopan; Luo, Tingyue; Yu, Sijian; Xu, Na; Sun, Zhiqiang; Lin, Dongjun; Deng, Lan; Liang, Xinquan; Xiao, Jie; Zhang, Hongyu; Guo, Ziwen; Shao, Ruoyang; Du, Xin; Jin, Hua; Liu, Qifa |
| 6-Jan-2025 | Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study | Yu, Guopan; Zhang, Yu; Yu, Sijian; Yin, Zhao; Weng, Guangyang; Xu, Na; Du, Xin; Lin, Dongjun; Xiao, Jie; Sun, Zhiqiang; Zhang, Hongyu; Liang, Xinquan; Guo, Ziwen; Zhao, Weihua; Dai, Min; Fan, Zhiping; Xuan, Li; Liu, Hui; Xu, Dan; Ye, Jieyu; Jiang, Xuejie; Shi, Pengcheng; Jin, Hua; Liu, Qifa |
| 2023 | Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study | Weng, Guangyang; Huang, Jingya; He, Xin; Xue, Tingting; Yang, Linlin; Zhang, Yu; Yu, Guopan; Sun, Zhiqiang; Lin, Dongjun; Deng, Lan; Liang, Xinquan; Xiao, Jie; Zhang, Hongyu; Guo, Ziwen; Jin, Hua; Liu, Qifa; Du, Xin |
| 6-Jul-2021 | Identifying the Persistent Free Radicals (PFRs) Formed as Crucial Metastable Intermediates during Peroxymonosulfate (PMS) Activation by N-Doped Carbonaceous Materials | Zhen, Yufei; Zhu, Shishu; Sun, Zhiqiang; Tian, Yu; Li, Zeng; Yang, Chen; Ma, Jun |
| 15-Nov-2022 | Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia | Yu, Guopan; Yin, Zhao; Jin, Hua; Yu, Sijian; Li, Yuhua; Nie, Danian; Guo, Ziwen; Sun, Zhiqiang; Meng, Qingxiang; Zhao, Weihua; Lin, Dongjun; Xu, Na; Zhang, Yu |
| 15-Sep-2022 | Microenvironmentally optimized 3D-printed TGF ?-functionalized scaffolds facilitate endogenous cartilage regeneration in sheep | Yang, Zhen; Cao, Fuyang; Li, Hao; He, Songlin; Zhao, Tianyuan; Deng, Haoyuan; Li, Jianwei; Sun, Zhiqiang; Hao, Chunxiang; Xu, Jianzhong; Guo, Quanyi; Liu, Shuyun; Guo, Weimin |
| 16-Nov-2021 | Oxygen Vacancy-Induced Nonradical Degradation of Organics: Critical Trigger of Oxygen (O-2) in the Fe-Co LDH/Peroxymonosulfate System | Wu, Liying; Sun, Zhiqiang; Zhen, Yufei; Zhu, Shishu; Yang, Chen; Lu, Jing; Tian, Yu; Zhong, Dan; Ma, Jun |
| 22-Mar-2021 | Recent Developed Strategies for Enhancing Chondrogenic Differentiation of MSC: Impact on MSC-Based Therapy for Cartilage Regeneration | Zha, Kangkang; Sun, Zhiqiang; Yang, Yu; Chen, Mingxue; Gao, Cangjiang; Fu, Liwei; Li, Hao; Sui, Xiang; Guo, Quanyi; Liu, Shuyun |
| 2023 | Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with <i>FLT3-ITD</i>: A multicenter phase 2 study | Yu, Sijian; Zhang, Yu; Yu, Guopan; Wang, Yu; Shao, Ruoyang; Du, Xin; Xu, Na; Lin, Dongjun; Zhao, Weihua; Zhang, Xiong; Xiao, Jie; Sun, Zhiqiang; Deng, Lan; Liang, Xinquan; Zhang, Hongyu; Guo, Ziwen; Dai, Min; Shi, Pengcheng; Huang, Fen; Fan, Zhiping; Liu, Qiong; Lin, Ren; Jiang, Xuejie; Xuan, Li; Liu, Qifa; Jin, Hua |
| 2012 | Synthesis and catalysis of oleic acid-coated Fe3O4 nanocrystals for direct coal liquefaction | Li, Yizhao; Ma, Fengyun; Su, Xintai; Sun, Chao; Liu, Jianchao; Sun, Zhiqiang; Hou, Yanglong |
| 29-Apr-2023 | Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial | Jin, Hua; Zhang, Yu; Yu, Sijian; Du, Xin; Xu, Na; Shao, Ruoyang; Lin, Dongjun; Chen, Yanqiu; Xiao, Jie; Sun, Zhiqiang; Deng, Lan; Liang, Xinquan; Zhang, Hongyu; Guo, Ziwen; Dai, Min; Shi, Pengcheng; Huang, Fen; Fan, Zhiping; Yin, Zhao; Xuan, Li; Lin, Ren; Jiang, Xuejie; Yu, Guopan; Liu, Qifa |
| 29-Apr-2023 | Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial | Jin, Hua; Zhang, Yu; Yu, Sijian; Du, Xin; Xu, Na; Shao, Ruoyang; Lin, Dongjun; Chen, Yanqiu; Xiao, Jie; Sun, Zhiqiang; Deng, Lan; Liang, Xinquan; Zhang, Hongyu; Guo, Ziwen; Dai, Min; Shi, Pengcheng; Huang, Fen; Fan, Zhiping; Yin, Zhao; Xuan, Li; Lin, Ren; Jiang, Xuejie; Yu, Guopan; Liu, Qifa |
